Acquisition of resistance to
gemcitabine is a challenging clinical and biological hallmark property of refractory
pancreatic cancer. Here, we investigated whether
glycogen synthase kinase (GSK)-3β, an emerging therapeutic target in various
cancer types, is mechanistically involved in acquired resistance to
gemcitabine in human
pancreatic cancer. This study included 3
gemcitabine-sensitive BxPC-3 cell-derived clones (BxG30, BxG140, BxG400) that acquired stepwise resistance to
gemcitabine and overexpressed
ribonucleotide reductase (RR)M1. Treatment with GSK3β-specific inhibitor alone attenuated the viability and proliferation of the
gemcitabine-resistant clones, while synergistically enhancing the efficacy of
gemcitabine against these clones and their xenograft
tumors in rodents. The
gemcitabine-resensitizing effect of GSK3β inhibition was associated with decreased expression of RRM1, reduced phosphorylation of
Rb protein, and restored binding of Rb to the E2
transcription factor (E2F)1. This was followed by decreased E2F1 transcriptional activity, which ultimately suppressed the expression of E2F1 transcriptional targets including RRM1, CCND1 encoding
cyclin D1,
thymidylate synthase, and
thymidine kinase 1. These results suggested that GSK3β participates in the acquisition of
gemcitabine resistance by
pancreatic cancer cells via impairment of the functional interaction between Rb
tumor suppressor protein and E2F1 pro-oncogenic
transcription factor, thereby highlighting GSK3β as a promising target in refractory
pancreatic cancer. By providing insight into the molecular mechanism of
gemcitabine resistance, this study identified a potentially novel strategy for
pancreatic cancer chemotherapy.